Lurie Children’s Hospital Selects Grifols KIRO® Robot to Increase Precision, Safety, and Compliance of Pediatric IV Chemotherapy Handling and Compounding

  • Grifols KIRO robotic system provides next-generation precision and
    automation for sterile compounding of IV medications.
  • System modernizes the sterile compounding of IV medications to improve
    accuracy and compliance.
  • Lurie Children’s will use the system to enhance both patient and staff
    safety.

CHICAGO & LOS ANGELES–(BUSINESS WIRE)–The Ann & Robert H. Lurie Children’s Hospital of Chicago, one of the top
pediatric care hospitals in the United States, has partnered with
Grifols, a global healthcare company with more than 75 years of history
maintaining the highest quality and safety standards in its own
manufacturing processes, to advance patient and staff safety with the
Grifols KIRO Oncology robotic system.


At Lurie Children’s, the Grifols KIRO Oncology system will provide
precision and control during compounding of sterile IV (intravenous)
chemotherapies for pediatric patients, whose smaller bodies are more
sensitive to even minute variations in drug doses. The system also helps
to improve compliance and environmental safety, as well as waste
reduction and overall IV room operational efficiency.

“The Grifols KIRO robot enhances patient safety by performing barcoding
check of all products used and gravimetric control based on the drug’s
specific gravity. Its accuracy exceeds the volume demarcations on the
syringe,” said Jenny Elhadary, Vice President of Clinical Operations at
Lurie Children’s. “It also provides staff safety by reducing their
exposure to hazardous drugs and protecting them from repeated stress
injury.”

The correct preparation of sterile individualized drug doses is a
complex process. The ability to achieve exact accuracy to prescribed
doses can be influenced by several factors, such as limits in the
measurement precision of syringes and other equipment, natural
variations in manual processing, and FDA-allowed variations in products
received from manufacturers. The Grifols KIRO Oncology system is
designed specifically to address these challenges and facilitate
compliance with best practices and regulations.

The Grifols KIRO Oncology system accommodates a variety of sizes and
manufacturers’ bags, syringes, and cassettes. It can prepare
patient-specific doses and small batches using liquid and lyophilized
drugs. Uniquely designed with two robotic arms, the system is able to
perform vial reconstitution and bag filling in parallel – just one
example of the separate tasks the robot can achieve simultaneously.

The system performs gravimetric checks at all stages of the compounding
process and releases final products based on their accuracy to
prescribed doses. Partially used vials are held and tracked within the
cabinet for subsequent dose preparation, helping to minimize waste of
costly drugs.

In-process barcode readers and cameras precisely identify vials, bags,
and disposables by comparing readings and images taken during processing
with those in the Grifols KIRO Oncology system’s database.

Safety-critical compounding operations, as well as the system’s unique
automated cleaning process, take place in a completely enclosed
environment. The system’s ISO 5 class environment protects users and the
environment from unintended exposure to hazardous drugs during loading
and automated compounding processes. The KIRO Oncology system can also
be integrated as a biosafety class II cabinet in USP797 and
GMP-compliant facilities to support monitoring and qualification
procedures.

“Pharmacy operations have evolved to embrace the patient safety and
workflow benefits of advanced medication safety technologies,” said Bill
Churchill, M.S., R.Ph., Chief Pharmacy Officer at Brigham & Women’s
Healthcare in Boston. “Advanced robotic systems that aid pharmacy
specialists will be essential to modernizing sterile compounding
processes – many of which have not significantly changed in decades. In
addition to offsetting human and manufacturing variations, newer
technologies can help pharmacies more efficiently handle the influx of
new medications as well as the overall increase in workloads.”

About Grifols

Grifols
is a global healthcare company with more than 75 years of history
improving the health and well-being of people around the world through
the development of plasma medicines, hospital pharmacy products, and
diagnostic technology for clinical use. Grifols is present in more than
100 countries worldwide, with global headquarters in Barcelona, Spain.
In 2015, Grifols sales exceeded 3,934 million euros, with a headcount of
nearly 14,700 employees. Grifols demonstrates its commitment to
advancing healthcare by allocating a significant portion of its annual
income to R&D.

Through its Hospital Division, Grifols leverages its extensive in-house
expertise in engineering, manufacturing, and process control to deliver
consultative planning and a comprehensive suite of products and
services, including sophisticated robotic technology for compounding
sterile products in hospital pharmacies.

About the Ann & Robert Lurie Children’s Hospital of Chicago

Ann
& Robert H. Lurie Children’s Hospital
is ranked as one of the
nation’s top children’s hospitals in U.S. News & World Report
2015-16 Honor Roll. Founded in 1882, it is the pediatric training ground
for the Northwestern University Feinberg School of Medicine and one of
only a handful of U.S. children’s hospitals with a dedicated pediatric
research center, the Stanley Manne Children’s Research Institute. It was
the first children’s hospital in the country to receive the American
Nurses Credentialing Center’s Magnet Award for Nursing Excellence. Last
year, Lurie Children’s treated more than 174,000 patients.

Contacts

Lurie Children’s Hospital
Julie Pesch
Director
of Public Affairs & Communications
Phone (Direct): 312-227-4261
Phone
(Public Affairs): 312-227-4600
Email: jpesch@luriechildrens.org
or
Grifols
Melinda
Baker
Director of Corporate Communications
Mobile: 510-915-3787
Email: melinda.baker@grifols.com